<DOC>
	<DOC>NCT00676143</DOC>
	<brief_summary>This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable AD, with MMSE score of 1626, and brain MRI consistent with the diagnosis of AD Concurrent use of cholinesterase inhibitor or memantine allowed, if stable. Caregiver will participate and be able to attend clinic visits with patient. Significant neurological disease other than AD, or a major psychiatric disorder Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body) Woman of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>